Imagine trying to solve a puzzle where the pieces are scattered across different hospitals and written in different languages. This project builds a digital bridge that lets doctors securely combine a patient's genetic code with their medical records without moving the data from its original home. It's like having a universal translator and a secure vault for health data to find the right treatment for heart patients faster.
Integrating genomic and clinical data is currently too slow and complex due to privacy laws and incompatible data formats. This prevents doctors from using personalized medicine for heart disease at scale.
The project is building software for accelerated genomic analysis, a data discovery tool, and a system for federated genomic analysis across different locations.
If you are a drug discovery firm dealing with fragmented genomic data across borders — this project developed federated genomic analysis tools that allow you to identify disease markers without compromising patient privacy. This accelerates the development of personalized cardiovascular medicines.
If you are a medical software developer dealing with the complexity of multiomic data formats — this project developed an accelerated secondary genomic analysis prototype that improves clinical efficiency in variant prioritization. This reduces the time needed to deliver diagnostic results to clinicians.
If you are a hospital network dealing with strict data governance and privacy laws — this project developed a data discovery functionality and governance system aligned with the European Health Data Space. This enables secure multi-jurisdictional access to patient phenotypes for better heart disease monitoring.
Based on available project data, no specific pricing or commercial cost model is mentioned; the project received an EU contribution of EUR 7,601,770 for development.
The project focuses on scalable genomic data curation and a network of 5 collaborating clinical sites to prove the concept, suggesting a path toward industrial scaling.
Based on available project data, specific licensing terms are not listed, but the project includes an embedded governance system to manage secure data access.
The tools are designed to align with the '1+ Million Genomes' initiative and the European Health Data Space to ensure secure, multi-jurisdictional data access.
The project period runs from 2024-01-01 to 2027-12-31, with initial prototypes for genomic analysis and data discovery already being developed.
The consortium is well-balanced for commercialization, featuring 21 partners across 10 countries. With a 24% industry ratio (5 companies, including 3 SMEs), there is a strong link between academic research (8 universities) and market application. The inclusion of US and European partners suggests a high potential for cross-border data standard adoption.
Contact Universitair Medisch Centrum Utrecht
Contact us to explore licensing opportunities for the NextGen genomic analysis prototypes.
